OTC Watch

All stocks / INBP

INTEGRATED BIOPHARMA INC INBP

Integrated Biopharma (INBP): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated float OTCQXNew Jersey, USA
Live quote on OTC Markets

Market listing

Full name
INTEGRATED BIOPHARMA INC
Market tier
OTCQX US
Trading status
Active
Last trade
Nov 16
Source: Stockwatch, 2026-11-17

News headlines

Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026
2026-11-13 12:07 · News Release
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
2026-09-25 17:00 · News Release
Integrated Biopharma's Wholly-Owned Subsidiary, Manhattan Drug Company, Inc. Appoints Michael Richtmyer as Head of Operations
2026-08-20 10:00 · News Release
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
2026-05-08 16:30 · News Release
Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025
2026-02-11 16:30 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2026-06-30
The report says
Net loss
($2,842,000)
What it means

It spends more than it earns

Under strain

The company lost $2.8 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$4,471,000
Net cash from operating activities
$1,241,000
What it means

The business brings in cash

Steady

Day-to-day business added $1.2 million in cash over the year. It had $4.5 million in the bank.

The report says
Total assets
$25,338,000
Total liabilities
$7,671,000
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $25.3 million. Its debts and unpaid bills add up to $7.7 million. That is about $0.30 owed for every $1 owned.

What this adds up to

1 of 3 checks show strain. It spends more than it earns. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-13

Estimated float about 18,187,885 shares as of 2026-11-13: 31,059,610 outstanding minus 12,871,725 held by 3 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-12-31
31.1M
2026-02-11
31.1M
2026-03-31
31.1M
2026-05-08
31.1M
2026-06-30
31.1M
2026-09-23
31.1M
2026-09-30
31.1M
2026-11-13
31.1M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-13 10-QFORM 10-Q
2026-11-13 8-KFORM 8-K
2026-10-28 DEF 14AFORM DEF 14A
2026-09-25 10-KFORM 10-K
2026-09-25 8-KFORM 8-K
2026-08-20 8-KFORM 8-K
2026-07-02 8-KFORM 8-K PNC FIRST AMENDMENT
2026-06-25 4PRIMARY DOCUMENT
2026-06-25 4PRIMARY DOCUMENT
2026-06-25 4PRIMARY DOCUMENT
2026-06-25 4PRIMARY DOCUMENT
2026-06-25 4/APRIMARY DOCUMENT

Common questions about INBP

Does INBP file reports with the SEC?

Yes. Integrated Biopharma files with the SEC under company number 0001016504. The most recent filing we hold is a 10-Q dated 2026-11-13.

Source record

How many INBP shares are outstanding?

31,059,610 shares as of 2026-11-13, as reported to the SEC.

Source record

Has INBP filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Integrated Biopharma?

Officers named in its insider filings: Christina Kay (Co-Chief Executive Officer), Dina Masi (Chief Financial Officer) and Sheppard Riva (Co-Chief Executive Officer).

Source record

Is Integrated Biopharma making money?

The company lost $2.8 million in the year. It reported no sales. (Annual figures to 2026-06-30. Facts from the company's own report, not a recommendation.)

Source record